Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
1.950
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellectis S.A. ADR
< Previous
1
2
3
4
5
6
Next >
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 22, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials
December 13, 2022
Via
Benzinga
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
December 13, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
December 01, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis's Earnings Outlook
November 02, 2022
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will...
Via
Benzinga
Cellectis to Report Third Quarter 2022 Financial Results
October 27, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
October 11, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
October 10, 2022
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 07, 2022
Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million.
Via
Benzinga
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
September 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
11 Health Care Stocks Moving In Friday's Pre-Market Session
September 23, 2022
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.
Via
Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
September 26, 2022
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Via
Benzinga
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
September 23, 2022
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day...
Via
Benzinga
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket
September 23, 2022
Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading.
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 01, 2022
Via
Benzinga
Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study
August 01, 2022
The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis' (NASDAQ: CLLS) Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 14, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 22, 2022
Via
Benzinga
71 Biggest Movers From Yesterday
May 20, 2022
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
May 19, 2022
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
May 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 17, 2022
Via
Benzinga
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut
April 27, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.